FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPRO\	/AL
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

\Box	Check this box if no longer subject to Section
	16. Form 4 or Form 5 obligations may continue.
$\overline{}$	See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

							,			· ·								
Name and Address of Reporting Person* Stalfort John A III					2. Issuer Name and Ticker or Trading Symbol <u>Acumen Pharmaceuticals, Inc.</u> [ABOS]						(Check	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
<u>Starrort s Griff 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 </u>				⊢									X	Director			10% Owi	ner
(Last)	(First)	(Mi	ddle)		3. Date of Earliest Transaction (Month/Day/Year) 06/06/2023						Officer (give below)	title		Other (sp	pecify below)			
C/O ACUMEN PHARM 427 PARK STREET	MACEUT	TCALS, INC.		4.	If Amend	dment, Date	e of Origina	al Filed (M	onth/l	Day/Year)			6. Indivi	dual or Joint/Gro Form filed by Form filed by	One Rep	oorting F		
(Street)				⊢														
CHARLOTTESVILLE	E VA	22	2902	R	Rule 1	0b5-1(c	c) Tran	sactior	ı In	dicatio	n							
(City)	(State)	(Zip	o)		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
''''''''			Date	Month/Day/Year) if any		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposition (D) (Instr. 3, 4 and 5)			isposed Of	Beneficially Own		ned Form: Direct (I)		7. Nature of Indirect Beneficial				
						(Month/	Day/Year)	Code	v	Amount		(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)				Ownership (Instr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
OI P	conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	n Date, Code (Instr. 8) Derivative Expiration Date Securities Acquired (Month/Day/Ye			n Date	е	Underlying Derivative S			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	ve es ially ng	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisal	ole [Expiration Date	Title		Amount or Number of Shares		Transac (Instr. 4)	tion(s)		
Stock Option (right to buy)	\$5.2	06/06/2023		A		25,000		(1)	(06/05/2033	Comm	non Stock	25,000	\$0	25,0	000	D	

Explanation of Responses:

1. The shares subject to the option will vest on the earlier of June 6, 2024 or the 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date.

Remarks:

/s/ Derek Meisner, Attorney-in-Fact 06/07/2023

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

 ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

The undersigned hereby constitutes and appoints Daniel O'Connell, Derek Meisner, Matthew Zuga and Thomas Danielski, and each of them singly, with full power of substitution, as the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as officer and/or director of Acumen Pharmaceuticals, Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the U.S. Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to such attorneys-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorneys-in-fact, or such attorneys-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

[Remainder of page intentionally left blank]

this 1	IN WITNESS WHER st day of June 2023.	EOF, the undersigned ha	s caused this Power of At	torney to be executed as	of
			/s/ Sean Stalfo Sean Stalfort	<u>rt</u>	
		[Signature Page to Limite	ed Power of Attorneyl		
		[S.G. S.			